Organon & Co. (OGN)
Automate Your Wheel Strategy on OGN
With Tiblio's Option Bot, you can configure your own wheel strategy including OGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OGN
- Rev/Share 24.4084
- Book/Share 2.1019
- PB 4.4912
- Debt/Equity 16.524
- CurrentRatio 1.6715
- ROIC 0.1476
- MktCap 2453984640.0
- FreeCF/Share 2.5246
- PFCF 3.7696
- PE 3.2456
- Debt/Assets 0.6808
- DivYield 0.0911
- ROE 1.8171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OGN | Evercore ISI | Outperform | In-line | -- | -- | May 2, 2025 |
| Downgrade | OGN | JP Morgan | Neutral | Underweight | $18 | $20 | Sept. 6, 2024 |
News
Organon: Management Slashes Dividend - This Feels Disastrous
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Negative
Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its Established Brands division, exacerbated by the patent expiry of key drugs. Management's rationale for cutting the dividend to manage debt and pursue M&A opportunities appears flawed, as it fails to address core financial issues.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Organon & Co. (OGN) Shareholders Who May Have Been Affected by Fraud
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Stockholders to Learn More About the Investigation
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Organon & Co. (OGN)
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Read More
Levi & Korsinsky Reminds Organon & Co. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - OGN
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Organon & Co. (OGN)
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Investors to Reach Out
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Read More
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Organon & Co. (OGN)
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Did Organon & Co. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - OGN
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Read More
Why The Low Payout Ratio Did Not Stop The Dividend Cut For Organon
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon boasted of a sub-33% dividend payout ratio.
Read More
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN.
Read More
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Organon & Co. (OGN) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Juan Camilo Arjona Ferreira - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan Umer Raffat - Evercore ISI Bhavin Patel - Bank of America Operator Hello, and welcome to the Organon First Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.
Read More
Organon (OGN) Q1 Earnings Surpass Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago.
Read More
Organon Reports Results for the First Quarter Ended March 31, 2025
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports earnings results for Q1 2025, ended March 31, 2025.
Read More
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Why Organon (OGN) Could Beat Earnings Estimates Again
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
Read More
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
About Organon & Co. (OGN)
- IPO Date 2021-05-14
- Website https://www.organon.com
- Industry Drug Manufacturers - General
- CEO Mr. Kevin Ali
- Employees 10000